Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug research, development and life-cycle decisions.
Our services are focused on drug usage and health care for a broad range of client types: pharmaceutical industry, government and non-government agencies, and not-for-profit organizations.
We operate in the areas of model-informed drug development, pharmacometrics, clinical pharmacology, statistics, physiologically based pharmacokinetics, quantitative systems pharmacology, biopharmaceutics, and regulatory strategy.
Our enthusiastic, dynamic, and experienced team ensures the supply of high-quality, timely and joined-up deliverables, compatible with the latest regulatory standards. The nature and extent of services we provide is determined on the basis of client need, from smaller projects in support of limited questions, through to larger late-phase projects including submission support and post-marketing analyses.
Pharmetheus currently has a team of more than 60 affiliates, located across a variety of countries globally, and we continue to grow. Our staff members come from diverse (and complementary) educational and technical backgrounds, with extensive experience of both standard and complex data analysis to enable fit for purpose deliverables for our clients.
Pharmetheus has dedicated data programming, QC and medical writing teams. We have developed systems, processes, and tools employing state-of-the-art project and quality control processes to accommodate the dynamic nature of drug development, and facilitate rapid delivery of even the largest project.
Our vision is to realize the full potential of quantitative approaches to improve health
Our strength is to deliver timely and reproducible model-informed drug development services: from efficient routine analyses to innovative solutions for complex systems
At the core of all our work are our agreed common values
For Pharmetheus, our corporate social responsibility (CSR) ambitions are to become an even more sustainable and responsible company. Like all initiatives within Pharmetheus, our CSR strategy stems from our vision and core values.
Out of the 17 United Nation’s Global Development Goals, we have chosen four goals to focus on for the coming five years. These goals are close to our core business and are perceived as natural, relevant, and fit-for-purpose activities.
Pharmetheus recognizes the risks posed by global climate change and their potential negative impact on human health.
In 2022, we will focus on documenting our strategy for the refurbishment of IT equipment
It is our belief that sharing knowledge, inspiring, and helping to learn is not only what we do best but also a way to create a better world.
In 2022, we will focus on extending university collaborations
Pharmetheus promotes equal rights and opportunities in the society as well as in the workplace, regardless of gender, ethnic origin, nationality, religious beliefs, sexual orientation, or other factors.
In 2022, we will focus on translating pharmacometrics courses from English to French as to enable French-speaking African students to access this knowledge.
Our vision […] is to improve health.
In 2022, we will focus on promoting physical activity through an internal sport challenge aimed at reaching sufficient levels of weekly exercise
At Pharmetheus, we support and encourage both technical and role based training. Learning is one element of our core values and it is enacted by a variety of means including presentations of ongoing work, peer group training, courses and advice from both our academic scientific advisors and external international experts. Such knowledge sharing not only contributes towards the excellence of our deliverables, but it also fosters more effective collaborations (another element of our core values). Some of our presentations and courses have been made available to our clients and please feel free to contact us if you would like to find out more.
Dr. Peter Milligan, CEO
“Effective feedback and feedforward of information across and within compounds can promote an environment of “joined-up thinking” within organizations. This is an important element of Model-Informed Drug Development (MIDD) as we obtain insights on a compound’s properties by efficiently leveraging accumulated data. These insights can be used to frame the most impactful compound-related risks and shape contingency plans that enable these risks to be managed/mitigated appropriately. MIDD can greatly aid the ability of decision makers to arrive at strategy and/or design achieving a favorable outcome.
At Pharmetheus we understand the importance of joined-up thinking. We have experience of adopting “fit-for-purpose” activities and we can assist our partners to overcome their technical and/or organizational challenges.”
Dr. Peter Milligan, Chief Executive Officer
“Pharmetheus’ team operates with integrity at the highest ethical and scientific standards. In close collaboration with our clients, applying innovative solutions, and in a time- and cost–efficient manner we are dedicated to address their questions to facilitate a shortened development time for safe and efficacious treatments.
How can we support your case?”
Dr. Marie Sandström, Chief Operations Officer
Dr Marie Sandström, COO
Emma Ångström, CFO
“Pharmetheus has had fantastic growth over the years. Our clients (>60) range from big pharma to small biotech companies which the vast majority are repeat business. We have a stable and healthy financial situation which is one of the pillars that ensures a long-term sustainability of the company. It allows us to continue to grow and develop Pharmetheus, to create value to the industry in collaboration with our clients and stakeholders and to offer a creative and learning environment to our employees.”
Emma Ångström, Chief Financial Officer
The Pharmetheus story began in 2012, when a team composed of experienced consultants, leaders from the pharmaceutical industry, and researchers from Uppsala University formed Pharmetheus, offering pharmacometric consultancy services with the overall aim to improve patients’ lives.
In 2001 Mats Karlsson (Pharmetheus’ Chairman of the Board) was appointed Professor of Pharmacometrics at Uppsala University. This was the world’s first professorship for this scientific discipline.
Since then, Prof. Mats Karlsson has established the pharmacometrics research group at Uppsala University to a world-leading position in developing methodology and applications for model-informed drug development (MIDD). This research has been an important steppingstone leading up to the formation of Pharmetheus.
Over time and with the recruitment of additional experts, our core business focus has gradually broadened to support a wide range of reproducible MIDD services: from efficient routine analyses to innovative solutions for complex systems.
The geographical footprint has also grown from our first small office in Uppsala. While the head office remains in Uppsala, today we have co-workers in more than 10 geographical locations in Europe and North America.
Today, we are active across all phases of research and development and across a wide range of therapeutic areas. Our team of competent consultants continuously provides strategic advice and fit-for-purpose analyses to support a wide variety of drug development decisions.
“Pharmacometrics is an applied science where research and application occur in both academia and industry. This has characterized its evolution. Academia develops methodology for improved applications and industry develops and implements methodology to support application needs. The exchanges of ideas, tools, and experiences between the organizations speed up the maturation of our field and promote model-informed drug discovery, development and usage. Pharmetheus is at the cross-roads of these activities and an active contributor in its own right.”
Prof. Mats Karlsson
Prof. Mats Karlsson
Dr. Martin Bergstrand
“Inspiration for the name Pharmetheus came from the titan Prometheus in Greek mythology. Prometheus was known for his intelligence and as a champion of mankind. The name Prometheus means approximately ‘the one that thinks on beforehand‘, his brother Epimetheus’ name means ‘the one that thinks afterwards’. We can think of Pharmetheus as the lesser-known sibling ‘the one that thinks of Pharma’.”
Dr. Martin Bergstrand
“When founding Pharmetheus, we had the vision – to realize the full potential of quantitative approaches, impacting decision making. This naturally led us to a philosophy of being a partner to our clients, and to a commitment of delivering with the highest quality. In practice, we always engage with our clients to identify their needs, to provide tailored value and for effective communication of results. The Pharmetheus culture still today reflects our ambition of bringing learning to the projects in all of its aspects.”
Dr. Elodie Plan
Dr. Elodie Plan
Dr. Niclas Jonsson
Dr. Mats Magnusson
“Our vision when creating the reproducible reporting system used at Pharmetheus was to support a fully traceable and auto-documented workflow for Pharmacometric analyses – from source data to final report. We are very proud of having accomplished this and are grateful of the positive feedback we continuously receive about our reporting system from both clients and regulatory authorities.”
Dr. Niclas Jonsson and Dr. Mats Magnusson
Employee location (Office/Home office)
Employee location (Country)
*The Netherlands, Italy, Switzerland, Belgium,
Germany, Iceland, Ireland, Slovenia
Uppsala, Sweden (Main)
Utrecht, The Netherlands
Home offices in (2) North American countries
Home offices in (11) European countries